Follow The Ratings: Abzena Plc (LON:ABZA) Investors: finnCap Reaffirms “Buy” Rating, Sees GBX 100.00/Share

November 29, 2016 - By Richard Conner

Abzena Plc (LON:ABZA) Rating

London: In a report shared with investors and clients on Tuesday, 29 November, finnCap reaffirmed their “Buy” rating on shares of Abzena Plc (LON:ABZA). They currently have a GBX 100.00 target price on the firm. finnCap’s target suggests a potential upside of 207.69% from the company’s last stock close price.

Abzena PLC (LON:ABZA) Ratings Coverage

Out of 2 analysts covering Abzena Plc (LON:ABZA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 100 is the highest target while GBX 98 is the lowest. The GBX 99 average target is 205.56% above today’s (GBX 32.4) stock price. Abzena Plc has been the topic of 10 analyst reports since September 14, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by FinnCap on Friday, November 18. As per Thursday, January 7, the company rating was maintained by N+1 Singer. The stock has “Buy” rating given by N+1 Singer on Monday, September 14. N+1 Singer maintained the stock with “Corporate” rating in Tuesday, November 24 report. As per Monday, October 12, the company rating was maintained by N+1 Singer. The firm has “Buy” rating given on Monday, September 21 by N+1 Singer. The stock of Abzena PLC (LON:ABZA) has “Corporate” rating given on Thursday, November 24 by N+1 Singer. The rating was maintained by N+1 Singer with “Corporate” on Friday, October 21. N+1 Singer maintained the stock with “Corporate” rating in Monday, January 25 report.

Abzena PLC (LON:ABZA) has declined 35.00% since April 28, 2016 and is downtrending. It has underperformed by 40.26% the S&P500.

Abzena plc is a life sciences company. The company has a market cap of 44.57 million GBP. The Firm provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It currently has negative earnings. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Another recent and important Abzena PLC (LON:ABZA) news was published by Businesswire.com which published an article titled: “Abzena plc: Placing to Raise £20 Million and Acquisition” on November 24, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>